The administration of tocilizumab during a 12-week training period led to an ~8-fold enhanced increase in adiponectin levels (p = 0.01) in people with obesity, with or without type 2 diabetes, compared with the placebo-treated subjects. This evidence concerns the gene ADIPOQ and obesity disorder.